000			nab a22 7a 4500
999			_c16717 _d16717
003			PC16717
005			20220208132557.0
008			220208b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91178 _aBlázquez Gamero, Daniel _ePediatría
245	0	0	_a13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. _h[artículo]
260			_bPediatrics, _c2015
300			_a135(4):e876-86.
500			_aFormato Vancouver: Martinón Torres F, Czajka H, Center KJ, Wysocki J, Majda Stanislawska E, Omeñaca F et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015 Apr;135(4):e876-86.
501			_aPMID: 25780077
504			_aContiene 28 referencias
520			_aObjectives: This study evaluated the immune response and safety profile of 13-valent pneumococcal conjugate vaccine (PCV13) in preterm infants compared with term infants. Methods: This Phase IV, open-label, 2-arm, multicenter, parallel-group study enrolled 200 healthy infants (preterm, n = 100; term, n = 100) aged 42 to 98 days. All subjects received PCV13 at ages 2, 3, 4 (infant series), and 12 (toddler dose [TD]) months, together with routine vaccines (diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b vaccine and meningococcal group C conjugate vaccine). Results: Most subjects achieved an anticapsular immunoglobulin G (IgG) antibody concentration ≥ 0.35 μg/mL for all serotypes: >85% after the infant series (except preterm infants for serotypes 5, 6A, and 6B) and >97% after TD (except for serotype 3). Preterm infants had overall lower IgG geometric mean concentrations compared with term infants; however, geometric mean fold increases after TD were similar for all serotypes. Opsonophagocytic activity results were consistent with IgG results and titers increased after TD in both groups for all serotypes, including serotype 3. PCV13 was generally well tolerated, with similar safety profiles in all preterm subgroups. Conclusions: Immune responses were lower in preterm infants than in term infants. However, the majority of subjects in both groups achieved both pneumococcal serotype-specific IgG antibody levels after the infant series that exceeded the World Health Organization-established threshold of protection and functional antibody responses. Responses were uniformly higher after TD, reinforcing the importance of a timely booster dose. PCV13 was well tolerated regardless of gestational age.
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16717.pdf _ySolicitar documento
942			_2ddc _cART _n0